RhumbLine Advisers’s DIPLOMAT PHARMACY, INC. DPLO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-196,773
Closed -$787K 2951
2019
Q4
$787K Buy
196,773
+11,181
+6% +$52.5K ﹤0.01% 2184
2019
Q3
$909K Buy
185,592
+11,779
+7% +$65.9K ﹤0.01% 2078
2019
Q2
$1.06M Buy
173,813
+13,863
+9% +$73.7K ﹤0.01% 2049
2019
Q1
$929K Sell
159,950
-1,486
-0.9% -$15.3K ﹤0.01% 2072
2018
Q4
$2.17M Buy
161,436
+28,901
+22% +$487K ﹤0.01% 1593
2018
Q3
$2.57M Buy
132,535
+8,606
+7% +$183K 0.01% 1522
2018
Q2
$3.17M Buy
123,929
+7,800
+7% +$182K 0.01% 1402
2018
Q1
$2.34M Buy
116,129
+2,803
+2% +$65.4K ﹤0.01% 1510
2017
Q4
$2.27M Buy
113,326
+15,713
+16% +$309K ﹤0.01% 1555
2017
Q3
$2.02M Buy
97,613
+4,925
+5% +$83.3K ﹤0.01% 1621
2017
Q2
$1.37M Buy
92,688
+6,738
+8% +$112K ﹤0.01% 1778
2017
Q1
$1.37M Buy
85,950
+24,076
+39% +$347K ﹤0.01% 1762
2016
Q4
$780K Buy
61,874
+2,873
+5% +$53.5K ﹤0.01% 1988
2016
Q3
$1.65M Buy
59,001
+6,775
+13% +$227K ﹤0.01% 1532
2016
Q2
$1.83M Buy
52,226
+9,924
+23% +$312K 0.01% 1400
2016
Q1
$1.16M Buy
42,302
+6,765
+19% +$199K ﹤0.01% 1696
2015
Q4
$1.22M Buy
35,537
+3,550
+11% +$111K ﹤0.01% 1676
2015
Q3
$919K Buy
31,987
+1,382
+5% +$59.1K ﹤0.01% 1821
2015
Q2
$1.37M Buy
30,605
+19,405
+173% +$730K ﹤0.01% 1666
2015
Q1
$387K Buy
11,200
+3,150
+39% +$85.7K ﹤0.01% 2455
2014
Q4
$220K Buy
+8,050
New +$195K ﹤0.01% 2754

Other funds holding DPLO

RhumbLine Advisers's DPLO Position: Q1 2020 in Review

RhumbLine Advisers sold out of DIPLOMAT PHARMACY, INC. (DPLO) in Q1 2020, closing a stake of 196,773 shares — an estimated $787K sold.

RhumbLine Advisers first reported a position in DPLO in Q4 2014 and held it in 21 quarters. The position peaked at $3.17M in Q2 2018. 1 fund tracked by Wall St. Rank holds DPLO as of Q1 2020.

  • RhumbLine Advisers reported no remaining DIPLOMAT PHARMACY, INC. position as of Q1 2020 after selling out during the quarter.
  • RhumbLine Advisers sold 196,773 DIPLOMAT PHARMACY, INC. shares in Q1 2020, an estimated $787K.
  • RhumbLine Advisers first reported a position in DIPLOMAT PHARMACY, INC. in Q4 2014 and held it in 21 quarters.
  • RhumbLine Advisers's DIPLOMAT PHARMACY, INC. position peaked at $3.17M in Q2 2018.
  • 1 fund tracked by Wall St. Rank held DIPLOMAT PHARMACY, INC. as of Q1 2020.

Based on RhumbLine Advisers's 13F filing for Q1 2020, filed 6 May 2020.